We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$106M
Cap. Flow %
-1.64%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.58%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
26
Abbott
ABT
$190B
$78.9M 1.22%
938,000
+322,600
+52% +$25.4M
EHTH icon
27
eHealth
EHTH
$43.5M
$78.3M 1.21%
909,814
-271,400
-23% -$18.3M
ATNX
28
DELISTED
Athenex, Inc. Common Stock
ATNX
$76M 1.18%
192,007
+170,507
+793% +$47.3M
THOR
29
DELISTED
Synthorx, Inc. Common Stock
THOR
$71.8M 1.11%
5,316,355
– –
QURE icon
30
uniQure
QURE
$2.7B
$70.2M 1.09%
+897,800
New +$57.2M
MGTX icon
31
MeiraGTx Holdings
MGTX
$1.06B
$69.5M 1.08%
2,586,951
+126,700
+5% +$2.62M
REGN icon
32
Regeneron Pharmaceuticals
REGN
$73.1B
$67.5M 1.05%
215,800
+1,000
+0.5% +$333K
A icon
33
Agilent Technologies
A
$39.8B
$66.7M 1.03%
893,200
+94,500
+12% +$7M
BOLD
34
DELISTED
Audentes Therapeutics, Inc
BOLD
$64.9M 1%
1,713,069
-101,931
-6% -$3.92M
BMY icon
35
Bristol-Myers Squibb
BMY
$130B
$61M 0.94%
1,345,200
+150,200
+13% +$7M
ARVN icon
36
Arvinas
ARVN
$528M
$58.9M 0.91%
2,678,810
– –
PRNB
37
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$53.3M 0.83%
1,605,713
-1,000,000
-38% -$31.2M
ILMN icon
38
Illumina
ILMN
$29.4B
$51.6M 0.8%
144,126
-89,538
-38% -$28.3M
CRNX icon
39
Crinetics Pharmaceuticals
CRNX
$8.87B
$51M 0.79%
2,039,282
+125,000
+7% +$3.1M
ACET icon
40
Adicet Bio
ACET
$76.7M
$49.3M 0.76%
43,128
– –
MYOK
41
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$47.9M 0.74%
955,300
+48,700
+5% +$2.37M
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$46.2M 0.72%
1,823,700
+61,400
+3% +$1.25M
VRAY
43
DELISTED
ViewRay, Inc.
VRAY
$45.4M 0.7%
5,149,019
– –
ARGX icon
44
argenx
ARGX
$55B
$43.9M 0.68%
310,400
-50,900
-14% -$6.46M
ZLAB icon
45
Zai Lab
ZLAB
$2.05B
$40.8M 0.63%
1,169,000
-232,318
-17% -$6.84M
NXTC icon
46
NextCure
NXTC
$20.9M
$40.6M 0.63%
+225,918
New +$47M
CI icon
47
Cigna
CI
$78.7B
$39.8M 0.62%
252,600
– –
DXCM icon
48
DexCom
DXCM
$28.9B
$39.4M 0.61%
1,051,600
+496,800
+90% +$15.6M
TNDM icon
49
Tandem Diabetes Care
TNDM
$1.24B
$36.8M 0.57%
570,790
-60,510
-10% -$3.91M
PRTA icon
50
Prothena Corp
PRTA
$444M
$32.4M 0.5%
3,065,278
+630,000
+26% +$6.47M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.